During the past decade, Nippon Medical School Musashi Kosugi Hospital conducted 7 clinical trials. In the 10-year time frame, 7 clinical trials started and 3 clinical trials were completed, i.e. on average, 42.9% percent of trials that started reached the finish line to date. In the past 5 years, 3 clinical trials started and 3 clinical trials were completed. i.e. 100% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Nippon Medical School Musashi Kosugi Hospital" #1 sponsor was "Hoffmann-La Roche" with 2 trials, followed by "Takeda" with 2 trials sponsored, "Translational Research Center for Medical Innovation, Kobe, Hyogo, Japan" with 2 trials sponsored, "Clovis Oncology, Inc." with 1 trials sponsored and "Pfizer" with 1 trials sponsored. Other sponsors include -4 different institutions and companies that sponsored additional 6 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Nippon Medical School Musashi Kosugi Hospital" #1 collaborator was "Bristol-Myers Squibb" with 1 trials as a collaborator, "European Network of Gynaecological Oncological Trial Groups (ENGOT)" with 1 trials as a collaborator, "Foundation Medicine" with 1 trials as a collaborator, "Gynecologic Oncology Group" with 1 trials as a collaborator and "Nippon Medical School, Musashi Kosugi Hospital" with 1 trials as a collaborator. Other collaborators include -4 different institutions and companies that were collaborators in the rest 6 trials.

According to Clinical.Site data, the most researched conditions in "Nippon Medical School Musashi Kosugi Hospital" are "Fallopian Tube Cancer" (3 trials), "Ovarian Cancer" (3 trials), "Idiopathic Pulmonary Fibrosis" (2 trials), "Primary Peritoneal Cancer" (2 trials) and "Acute Ischemic Stroke" (1 trials). Many other conditions were trialed in "Nippon Medical School Musashi Kosugi Hospital" in a lesser frequency.

Most popular intervention types in "Nippon Medical School Musashi Kosugi Hospital" are "Drug" (7 trials) and "Biological" (1 trials). Other intervention types were less common.

The name of intervention was led by "Niraparib" (2 trials), "PRM-151 (Zinpentraxin Alfa)" (2 trials), "Nivolumab" (1 trials), "PLD" (1 trials) and "Placebo" (1 trials). Other intervention names were less common.

The vast majority of trials in "Nippon Medical School Musashi Kosugi Hospital" are 5 trials for "All" genders and 4 trials for "Female" genders.

Currently, there are NaN active trials in "Nippon Medical School Musashi Kosugi Hospital". 1 are not yet recruiting, undefined are recruiting, 1 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 6 completed trials in Nippon Medical School Musashi Kosugi Hospital, undefined suspended trials, and 1 terminated clinical trials to date.

Out of the total trials that were conducted in Nippon Medical School Musashi Kosugi Hospital, 0 "Phase 1" clinical trials were conducted, 2 "Phase 2" clinical trials and 5 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 0 trials, and there were also 0 trials that are defined as “Not Applicable".